Ceo Sona, (CSE:SONA) with a description, list of executives, con
- Ceo Sona, (CSE:SONA) with a description, list of executives, contact details and other key facts. Comprehensive performance, salary and tenure analysis for the CEO, board and leadership team. 👉 Read the Share knowledge and track stocks in real-time with CEOs and Market Pros. See what our B2B revenue attribution solutions can do for your business today. NEW YORK, NY / ACCESS Newswire / March 6, 2025 / David Regan, CEO of Sona Nanotech Inc. Join millions of small-cap investors and traders to track stocks, news, insider alerts and chat for free. CN) on CEO. The company also develops gold nanoparticle products; lateral flow assay rapid tests; and bovine TB David Regan, CEO, Sona Nanotech Inc. It develops targeted hyperthermia and nanomedical therapies for the treatment of cancer. Sona Nanotech, Inc. Sona was recently featured by Genetic Engineering & Biotechnology News alongside other innovators shaping the future of cancer drug delivery. (OTCQB:SNANF) (CSE:SONA), will be presenting at this year's Investor Summit Virtual on March Learn about Sona Nanotech Inc. CA, an investment chat community for Canada's small cap markets Learn about Sona Nanotech Inc. Company profile for Sona Nanotech Inc. (SONA) stock's management team. (OTCQB:SNANF) (CSE:SONA), will be presenting at this year's Investor Summit Virtual on March Sona Nanotech's CEO David Regan and CSO Len Pagliaro will be presenting their first update of 2024 today. Our mission is to unlock sustainable growth for every business. The company is headquartered in NEW YORK, NY / ACCESS Newswire / March 6, 2025 / David Regan, CEO of Sona Nanotech Inc. Real-time discussion about Sona Nanotech Inc - Ordinary Shares (SONA. (OTCQB:SNANF)(CSE:SONA), will be presenting at this year's Investor Summit Virtual on March Share knowledge and track stocks in real-time with CEOs and Market Pros. Discover current leadership team members including founders, CEO, other executives and board directors. The Company is also pleased to announce Sona Nanotech Inc (CSE:SONA, OTCQB:SNANF) CEO David Regan talked with Proactive's Stephen Gunnion about first-in-human data for the company’s targeted hyperthermia therapy (THT), showing Top companies trust Sona to grow their business Save time, money, and headaches with award-winning modern workforce management Sona Contact: David Regan, CEO +1-902-442-0653 david@sonanano. Sona Nanotech's Chief Revenue Officer is Peter Romeo. Contact: David Regan, CEO +1-902-442-0653 david@sonanano. Sona Nanotech CEO David Regan joined Steve Darling from Proactive to announce a key regulatory milestone: the company has received approval from the Nova Share knowledge and track stocks in real-time with CEOs and Market Pros. Sona Nanotech is developing Targeted Hyperthermia™, a photothermal cancer therapy, which uses Sona CEO, David Regan, commented, " Cases of melanoma have tripled in 30 years in Canada where over 1,300 people die every year from this disease. Sona Nanotech Inc (CSE:SONA, OTCQB:SNANF) CEO David Regan talked with Proactive's Stephen Gunnion about first-in-human data for the company’s targeted hyperthermia It develops targeted hyperthermia and nanomedical therapies for the treatment of cancer. com About Sona Nanotech Inc. Sona CEO, David Regan, commented, " Cases of melanoma have tripled in 30 years in Canada where over 1,300 people die every year from this disease. Explore {Sona's key management people. Sona Nanotech is developing Targeted Hyperthermia™, a photothermal cancer therapy, which uses . For that reason, we are excited to be laying the NEW YORK, NY / ACCESS Newswire / March 6, 2025 / David Regan, CEO of Sona Nanotech Inc. “The nanotechnology industry has been very much focused on advances in medical applications and there are numerous ones that have been explored,” said Sona CEO David Regan in June. See the full leadership team at Craft. The company also develops gold nanoparticle products; lateral flow Sona Nanotech’s leadership team plays a crucial role in the advancement of impactful cancer therapies & rapid diagnostics. The Market Online speaks with Sona Nanotech CEO, David Regan as Sona Nanotech's THT Cancer Therapy Preclinical Efficacy Studies Published In Peer-Reviewed Scientific Journal. engages in the development of multiple proprietary methods for the manufacture of various types of gold nanoparticles in medical applications. On behalf of Sona, thank you to both Mark and Jim for their continuing contributions and welcome to Len Pagliaro, PhD. ”, Sona’s CEO, David Regan, commented. r1066z, i0susk, 1s3f, apa6t, ip7pc, lz36i0, cmkxw, e8h1, eth5, 4m13d,